Recombinant Human VSIG8 Fc Chimera Protein, CF

Recombinant Human VSIG8 Fc Chimera (Catalog # 9200-VS)inhibits anti-CD3 antibody induced IL-2 secretion in human T lymphocytes. TheED50 for this effect is 1-5 μg/mL.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human VSIG8 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit anti-CD3 antibody induced IL-2 secretion in human T lymphocytes. The ED₅₀ for this effect is 1-5 μg/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human VSIG8 protein
  

  Human VSIG8 (Val22-Gly263) Accession # Q5VU13	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: Q5VU13
• N-terminal Sequence: Val22
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 54 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 56-64 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in Sodium Acetate, Mannitol and Trehalose.
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 200 μg/mL in Water.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human VSIG8 Fc Chimera Protein, CF

• V-set and immunoglobulin domain containing 8
• VSIG8

Background

VSIG8 (V-set and immunoglobulin domain containing 8), also known as C1orf204, is an approximately 45 kDa type I transmembrane protein of the B7 family within the Ig superfamily. Mature human VSIG8 consists of a 242 amino acid (aa) extracellular domain (ECD) containing two V-type Ig-like domains, a 21 aa transmembrane domain, and a 130 aa cytoplasmic domain. Within the ECD, human VSIG8 shares 88% and 89% aa identity with mouse and rat VSIG8, respectively. Alternative splicing generates a long isoform of human VSIG8 with a substitution in the cytoplasmic juxtamembrane region and a 124 aa extension at the C-terminus. VSIG8 was identified from proteomic analysis of human hair shafts (1, 2). It is expressed in the hair follicle and shaft, superficial layers of the nail matrix, and superficial layers of oral epithelium (3). R&D Systems in-house testing indicates that VSIG8 inhibits the production of IL-2 by activated T cells.

1. Rice, R.H. et al. (2010) J. Proteome Res. 9:6752.
2. Lee, Y.J. et al. (2006) Mol. Cell. Proteomics 5:789.
3. Rice, R.H. et al. (2011) J. Invest. Dermatol. 131:1936.

Bioinformatics

• Uniprot:
  • Q5VU13()